Palvella Therapeutics Announces Planned Pivotal Phase 3 Stud

QTORIN™ rapamycin has potential to become first approved therapy and standard of care for Microcystic Lymphatic Malformations in U.S.; significant commercial opportunity based on an estimated more than 30,000 individuals

Related Keywords

Japan , Marcy Nanus , Microcystic Lms , Wesleyh Kaupinen , Wes Kaupinen , Joycem Teng , Vishala Patel , European Medicines Agency , Trilon Advisors , Stanford University School Of Medicine , Gorlin Syndrome Alliance , Palvella Therapeutics Inc , Microcystic Lymphatic Malformations , Microcystic Lymphatic , Clinician Global Impression , Basal Cell Carcinomas , Gorlin Syndrome , Basal Cell Carcinoma , Clinically Suspicious , Biopsy Confirmed Basal Cell Carcinoma , Palvella Therapeutics , Chief Executive , Biopsy Confirmed , Global Impression , Lymphatic Malformations , Stanford University School , Orphan Drug , Fast Track Designations , Orphan Drug Designation , Associate Professor , Cutaneous Oncology , George Washington University School , Fast Track Designation , Track Designation ,